<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="163313">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02152696</url>
  </required_header>
  <id_info>
    <org_study_id>ACTorNOT</org_study_id>
    <nct_id>NCT02152696</nct_id>
  </id_info>
  <brief_title>Optimal Treatment for Women With a Persisting Pregnancy of Unknown Location</brief_title>
  <acronym>ACTorNOT</acronym>
  <official_title>Optimal Treatment for Women With a Persisting Pregnancy of Unknown Location - a Randomized Clinical Trial of Women at Risk for an Ectopic Pregnancy: Active Treatment Versus No Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Georgia Regents University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Penn State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of North Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized controlled trial to compare three currently available management
      strategies for women with a persisting pregnancy of unknown location (PPUL), which makes
      them at-risk for ectopic pregnancy. We will recruit hemodynamically stable women with a
      confirmed PPUL to be randomized to one of three strategies: 1) Uterine evacuation followed
      by methotrexate (MTX) for some (those that have evidence of a non visualized ectopic
      pregnancy) 2) Empiric treatment with MTX for all 3) Expectant management. Randomization will
      be 1:1:1 into these three arms. After randomization, they will be followed and treated
      clinically as is indicated by the progression of their condition. Primary outcome measures:
      uneventful decline of hCG to 5 IU/mL.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Uneventful clinical resolution of a Pregnancy of Unknown Location without change from the initial management strategy</measure>
    <time_frame>6 weeks from randomization</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary outcome measure in each of each 3 treatment arm is the uneventful clinical resolution of a PPUL without change from the initial management strategy.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">276</enrollment>
  <condition>Persistent Pregnancy of Unknown Location</condition>
  <condition>Ectopic Pregnancy</condition>
  <arm_group>
    <arm_group_label>Expectant Management</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will have their PPUL expectantly managed using serum hCG monitoring.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Uterine evacuation with MTX for some</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will undergo a uterine evacuation. If hCG levels do not sufficiently decrease after the uterine evacuation, the subject will be treated with methotrexate. If hCG levels do sufficiently decrease after the uterine evacuation, no further treatment is required.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Empiric treatment with MTX for all</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be treated with methotrexate, receiving one dose on day 0 and a subsequent dose on day 4. Additional doses will be administered as needed based on hCG levels.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Two Dose Protocol: The patient will receive the first dose of MTX 50mg/m2 on treatment day 0. She will receive a second dose of MTX 50mg/m2 on treatment day 4 and a serum hCG level will be drawn. Subsequent doses of MTX will be administered based on hCG levels.</description>
    <arm_group_label>Uterine evacuation with MTX for some</arm_group_label>
    <arm_group_label>Empiric treatment with MTX for all</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Uterine Evacuation</intervention_name>
    <description>Uterine evacuation or dilation and curettage. At the clinician's discretion, this can be performed using local anesthesia, sedation or general anesthesia and can use a manual or electrical evacuation.</description>
    <arm_group_label>Uterine evacuation with MTX for some</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Expectant Management</intervention_name>
    <description>Pregnancy will be expectantly managed using serum hcg monitoring</description>
    <arm_group_label>Expectant Management</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female with a persisting pregnancy of unknown location:

          -  A pregnancy of unknown location is defined as a pregnancy in a woman with a positive
             pregnancy test but no definitive signs of pregnancy in the uterus or adnexa on
             ultrasound imaging.  A definitive sign of gestation includes ultrasound visualization
             of a gestational sac with a yolk sac (with or without an embryo) in the uterus or in
             the adnexa.  Ultrasound must be performed within 7 days prior to randomization.

          -  Persistence of hCG is defined as at least 2 serial hCG values (over 4-14 days),
             showing &lt; 50% rise, or &lt; 50% fall between the first and last value.

          -  Patient is hemodynamically stable, hemoglobin &gt;10 mg/dL

          -  Greater than or 18 years of age

        Exclusion Criteria:

          -  Hemodynamically unstable in need of acute treatment

          -  Most recent hCG &gt; 5000 mIU/mL

          -  Patient obtaining care in relation to a recently completed pregnancy   (delivery,
             spontaneous or elective abortion)

          -  Diagnosis of gestational trophoblastic disease

          -  Subject unwilling or unable to comply with study procedures

          -  Presence of clinical contraindications for treatment with MTX

          -  Prior medical or surgical management of this gestation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Georgia Regents University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Connie Edwards</last_name>
      <phone>706-721-0193</phone>
      <email>coedwards@gru.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Diamond, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinny Eun</last_name>
      <phone>919-966-5283</phone>
      <email>jinny_eun@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Anne Steiner, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Rodriguez</last_name>
      <phone>405-271-1616</phone>
      <email>Michelle-Rodriguez@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Karl Hansen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pennsylvania State University</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jamie Ober</last_name>
      <phone>717-531-6272</phone>
      <email>jober@hmc.psu.edu</email>
    </contact>
    <investigator>
      <last_name>Richard Legro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Marunich</last_name>
      <phone>215-662-2935</phone>
      <email>RMarunich@obgyn.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ashley Singer</last_name>
      <email>Ashley.Singer@uphs.upenn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kurt Barnhart, MD, MSCE</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christos Coutifaris, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 28, 2014</lastchanged_date>
  <firstreceived_date>May 28, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Heping Zhang</investigator_full_name>
    <investigator_title>Primary Investigator</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pregnancy, Ectopic</mesh_term>
    <mesh_term>Cardiac Complexes, Premature</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
